Novartis vs Telix Pharmaceuticals
Novartis holds the stronger position because its broad, patent-protected drug portfolio and far larger financial base give it more room to absorb setbacks than Telix, which is smaller and still fighting for share against both Novartis and Lantheus.
Novartis
Swiss pharma giant selling patented medicines like Entresto, Kesimpta, and Pluvicto worldwide
Telix Pharmaceuticals
Telix makes PSMA-PET imaging drugs and radiopharmaceuticals for prostate cancer diagnosis and treatment
Dimension by dimension
| Dimension | Novartis | Telix Pharmaceuticals |
|---|---|---|
| Staying power of the core product | Novartis sells a wide range of patented medicines across many disease areas, including Entresto, Kesimpta, and Pluvicto. | Telix sells PSMA-PET imaging agents and is pushing into cancer radiotherapeutics, a newer and narrower business. |
| Exposure to AI | AI is unlikely to absorb Novartis's drug portfolio either. | AI is unlikely to absorb Telix's imaging and radiotherapy products. |
| How easily a giant copies them | Novartis's products are also blocked from easy copying. | Telix's products are blocked from easy copying. |
| Pressure from rivals | Novartis faces pressure from generic drug makers who won partial entry into Entresto, Promacta, and Tasigna after a June 2026 US court ruling. | Telix faces direct competition from Lantheus in PSMA-PET imaging and from Novartis itself as it enters radioligand therapy, where Novartis already dominates. |
| Financial footing | Novartis reported FY2025 net sales of $54.5B, up 8% at constant currency, with core operating income of $21.9B and a 40.1% core margin. | Telix reported Q2 2026 revenue of US$247M and guides for more than US$1 billion in FY2026 revenue including other income, with its Precision Medicine segment up 30% year over year. |
| Overall market standing | Novartis is described as built to last, with scale and margin that absorb competitive losses. | Telix is described as losing its protection, still building out its position in a market Novartis already leads. |
Questions people ask
- Telix Pharmaceuticals vs Novartis, which is better positioned for the AI era?
- Neither company's core products are exposed to AI absorption, since imaging agents and patented drugs are unlikely to be replaced by AI tools. Novartis is better positioned overall because of its much larger revenue base, broader drug portfolio, and higher margin, while Telix remains a smaller company still establishing its footing against bigger rivals including Novartis itself.
- Is Telix Pharmaceuticals a threat to Novartis?
- Telix is entering radioligand therapy, the same space where Novartis's Pluvicto and Lutathera already dominate, so it does add some competitive pressure. But Telix is much smaller than Novartis, with Q2 2026 revenue of US$247M against Novartis's FY2025 net sales of $54.5B, so the threat is limited for now.
- Who faces more competitive pressure, Telix or Novartis?
- Telix faces pressure from Lantheus in PSMA-PET imaging and from Novartis in radioligand therapy, a market Novartis already leads. Novartis faces pressure from generic drug makers gaining share on Entresto, Promacta, and Tasigna after a June 2026 US court ruling, but its broader portfolio cushions the impact more than Telix's narrower business can.
- Which company has stronger financials, Telix or Novartis?
- Novartis is far stronger financially, with FY2025 net sales of $54.5B, core operating income of $21.9B, and a 40.1% core margin. Telix is growing quickly, with Q2 2026 revenue of US$247M and FY2026 guidance above US$1 billion including other income, but it operates at a much smaller scale.
- Does either Telix or Novartis face a risk of AI replacing their products?
- No, AI absorption is considered unlikely for both companies. Telix's imaging agents and Novartis's patented drugs both depend on physical products and clinical approval processes that AI does not replace.
Other comparisons with these companies